Whitepaper: Turbocharging Raman measurements
This whitepaper describes the proprietary HyperFlux™ optical spectrometer designs developed by Tornado Spectral Systems.
List view / Grid view
This whitepaper describes the proprietary HyperFlux™ optical spectrometer designs developed by Tornado Spectral Systems.
A new partnership aims to improve blood-brain-barrier penetration in the nasal drug delivery route for certain Parkinson's therapies.
As the global COVID-19 response continues, so does the rapidly expanding pipeline for a novel COVID-19 vaccine. Here, experts from Avalere Health outline ongoing US and global vaccine development efforts, including the role of public-private partnerships in accelerating vaccine development. They will also focus on the broader context of respiratory…
Within this in-depth focus are articles explaining the numerous benefits of in vitro human cell-based kidney models to study nephrotoxicity and drug-to-drug interactions as well as discussing the measures taken by API manufacturers to successfully navigate the pandemic and the opportunities this presents.
11 December 2020 | By Metabolon
Watch our on-demand webinar as experts discuss the use and benefits of incorporating untargeted and targeted metabolomics into the drug development process.
The EC has approved an extension of marketing authorisation for Regeneron and Sanofi's Dupixent (dupilumab) for children aged six to 11 with severe atopic dermatitis.
A single-use, self-administered microneedle vaccine has been developed to provide immunisation against infectious diseases.
A new nasal spray with ingredients already approved for use in humans could be used to protect people against COVID-19.
Innocoll Holdings Limited has announced the commercial launch of the XARACOLL® (bupivacaine HCI) implant, a non-opioid treatment for acute post-surgical pain for up to 24 hours in adults following open inguinal hernia repair.
A major challenge in achieving clinically relevant oral delivery of biologics is overcoming the multiple physiological barriers in the gastrointestinal tract. In this article Nikki Withers discusses these challenges with Shawn Davis, Head of Drug Delivery, BioPharmaceuticals Development, R&D at AstraZeneca, who shares some of the latest advances in drug…
When a client gets an opportunity to expand rapidly, it takes a global partner to pull it off without a hitch.
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
A new report has shown that through the COVID-19 pandemic, the global nasal drug delivery technology market is predicted to increase.
Researchers have shown that mucoadhesive buccal films containing simvastatin inclusion complex and drug mixed micelles can improve the drug's bioavailability.
The ITAC trial will establish if adding hyperimmune intravenous immunoglobulin (hIVIG) to a remdesivir regimen can improve hospitalised COVID-19 patient outcomes.